Scinai Welcomes Liat Halpert as Head of Business Development and Sales
- None.
- None.
Insights
The appointment of Liat Halpert as Head of Business Development and Sales at Scinai Immunotherapeutics represents a strategic move that could potentially bolster the company's commercial efforts, particularly within its Scinai Bioservices CDMO unit. Halpert's track record in pharmaceutical sales and marketing, combined with her regional expertise, is expected to enhance the company's penetration into European and US markets. This could lead to an expansion of the company's client base and, subsequently, a diversification of revenue streams.
Halpert's role in out-licensing and partnering activities also indicates an aggressive strategy to commercialize Scinai's NanoAb therapeutics pipeline. Her experience may accelerate the process of bringing these products through clinical trials and into the market, addressing significant unmet medical needs in the inflammation and immunology space. The potential for Scinai's NanoAbs, particularly in the treatment of mild to moderate plaque psoriasis and COVID-19, could represent a considerable market opportunity given the current demand for innovative treatments in these areas.
Scinai Immunotherapeutics' focus on nanosized VHH antibodies (NanoAbs) for inflammation and immunology diseases is noteworthy due to the unique properties of NanoAbs, such as their small size, stability and ease of production. These attributes could lead to more effective, targeted therapies with potentially fewer side effects. The preclinical success of their IL-17 targeting NanoAb for psoriasis and the COVID-19 therapy, suggests a promising therapeutic pipeline.
However, the biotech industry is characterized by long development cycles and significant regulatory hurdles, which means that the anticipated entry into human clinical trials in 2025 for the psoriasis treatment is still subject to successful completion of ongoing studies and regulatory approval. The company's strategy to partner with mid and large cap pharma companies could mitigate some of the risks associated with clinical development and commercialization, leveraging the expertise and resources of established players in the industry.
The establishment of Scinai Bioservices as an end-to-end CDMO (Contract Development and Manufacturing Organization) is a significant development, tapping into the growing demand for outsourced biopharmaceutical services. With a GMP (Good Manufacturing Practice) facility, Scinai is positioning itself to offer a comprehensive suite of services from drug development to manufacturing. This vertical integration could lead to increased control over product quality and timelines, potentially reducing costs and accelerating time to market for clients.
Liat Halpert's expertise in marketing and commercial excellence, particularly in cell and gene therapies, is likely to be instrumental in navigating the complex regulatory landscape and ensuring compliance with international standards. Her experience may also prove valuable in establishing strategic partnerships that can extend the reach of Scinai Bioservices, transforming it into a significant revenue generator while supporting the growth of small biotech companies.
Scinai's broad pharmaceutical development experience, along with its end-to-end biologics drug development and GMP manufacturing facility, drove the Q3 2023 launch of Scinai Bioservices, a boutique end-to-end CDMO business unit, to assist biotech companies efficiently bring their products to market. The company has already signed contracts with several local biotech companies and is in advanced discussions with a number of other potential clients. Halpert's initial focus is to expand the business by targeting European and US-based biotech companies to support further growth of the CDMO business into a significant revenue generator for Scinai as well as a key partner for small biotechnology companies.
Scinai's R&D unit is focused on developing an innovative, de-risked pipeline of nanosized VHH antibodies (NanoAbs) licensed from the Max Planck Society and the University Medical Center Göttingen in
Amir Reichman, Scinai's CEO, commented, "I am pleased to welcome Liat to Scinai. Her pharmaceutical sales, marketing, and leadership experience, in particular in
Halpert commented, "I am thrilled to join Scinai where I'll be leading business development and sales of our state-of-the-art end-to-end CDMO services in the global biotech arena. I am also excited to support the partnering and business development efforts for Scinai's NanoAb therapeutics pipeline which in my opinion shows great potential for success. I believe Scinai's future is promising and bright, and I look forward to contributing and collaborating with the team."
Halpert holds an MSc. in Nutrition Science from the Hebrew University of
About Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with an innovative, de-risked pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing biological drug development, analytical methods development, clinical GMP manufacturing, and pre-clinical and clinical trial design and execution services to early stage biotech companies. Company website: www.scinai.com.
Company Contact
Investor Relations | +972 8 930 2529 | ir@scinai.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, the potential of Scinai's anti-IL-17 NanoAb, and the expansion of the CDMO business and the timing of human clinical trials. These forward-looking statements reflect management's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of Scinai Immunotherapeutics Ltd. Risks and uncertainties include, but are not limited to, the risk of delay in, or Scinai's inability to conduct, its research and development activities, including the contemplated in-vivo studies and a clinical trial; the risk that Scinai will not remain listed on Nasdaq; the risk that Scinai will not be successful in expanding its CDMO business or in-license other NanoAbs; the risk that Scinai may not be able to secure additional capital on attractive terms, if at all; the risk that the therapeutic and commercial potential of NanoAbs will not be met or that Scinai will not be successful in bringing the NanoAbs towards commercialization; the risk of a delay in the preclinical and clinical trials data for NanoAbs, if any; the risk that our business strategy may not be successful; the risk that the European Investment Bank (EIB) may accelerate the financial facility under its finance contract with Scinai; Scinai's ability to acquire rights to additional product opportunities; Scinai's ability to enter into collaborations on terms acceptable to Scinai or at all; timing of receipt of regulatory approval of Scinai's manufacturing facility in
Logo - https://mma.prnewswire.com/media/2310190/Scinai_Immunotherapeutics_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/scinai-welcomes-liat-halpert-as-head-of-business-development-and-sales-302060602.html
SOURCE Scinai Immunotherapeutics Ltd.
FAQ
What is the significance of Liat Halpert's appointment at Scinai Immunotherapeutics Ltd.?
What is the focus of Scinai's R&D unit?
What is the leading product in Scinai's pipeline?
What are the recent achievements in Scinai's preclinical trials?
What are the key responsibilities of Liat Halpert at Scinai Immunotherapeutics Ltd.?
